Abstract
The effect of inhaled beclomethasone dipropionate (BDP) using the spaser (InspirEase) was studied in 24 children (aged three to six years) with moderate to severe bronchial asthma. Seventeen patients were receiving BDP for six weeks after control 2 weeks and seven control subjects were receiving no corticosteroid therapy.
1) Frequency of minor attack of bronchial asthma was decreased within two weeks after this therapy started, especially in children receiving 300μg/day of BDP.
2) Peak flow rate was increased within first two weeks in many cases.
3) Serum cortisol levels were decreased in some cases. Oral candidiasis was not observed in any patients. These data suggested that BDI therapy using the spacer was effective on control of moderate to severe childhood asthma.
